长春高新表示，该笔款项的到账，进一步充盈了公司的现金储备，也为公司后续管线研发和国际化战略 的推进提供助力。 据了解，2025年12月15日，赛增医疗与Yarrow签订GenSci098注射液项目独家许可协议。根据协议，赛 增医疗作为技术许可方，将GenSci098注射液除大中华区 （中国大陆、香港特别行政区、澳门特别行政 区及台湾地区）以外的全球独家开发、生产和商业化权利授权给Yarrow。 北京商报讯（记者 丁宁）1月15日晚间，长春高新（000661）发布公告称，公司近日获悉，控股子公司 长春金赛药业有限责任公司下属全资子公司上海赛增医疗科技有限公司 （以下简称 "赛增医疗" ） 已根 据其与Yarrow Bioscience,Inc.（以下简称"Yarrow"）就GenSci098注射液项目订立的独家许可协议，收到 Yarrow一次性支付的7000万美元首笔付款。 ...

人民财讯1月15日电，长春高新（000661）1月15日披露GenSci098注射液项目签署独家许可协议的进 展：公司控股子公司金赛药业下属全资子公司赛增医疗已根据其与Yarrow就GenSci098注射液项目订立 的独家许可协议，收到Yarrow一次性支付的7000万美元首笔付款。GenSci098注射液是金赛药业自主研 发的一种人源化促甲状腺激素受体(TSHR)拮抗型单克隆抗体，为治疗用生物制品1类新药。 ...

证券代码：000661 证券简称：长春高新 公告编号：2026-003 长春高新技术产业（集团）股份有限公司 关于 GenSci098 注射液项目签署独家许可协议的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 二、有关 GenSci098 注射液项目 1 GenSci098 注射液是金赛药业自主研发的一种人源化促甲状腺激素受体 （TSHR）拮抗型单克隆抗体，为治疗用生物制品 1 类新药。通过特异性与甲状 腺或球后组织内 TSHR 结合，阻断其与自身抗体结合，进而抑制甲状腺激素的合 成和释放、抑制甲状腺细胞的增殖、阻止 HA 和炎症因子释放，从而发挥改善甲 亢的作用，并同时具有改善突眼的作用。本品临床前数据、在研的甲状腺眼病 （TED）的 I 期临床研究以及同靶点其他药物的临床数据表明，GenSci098 有潜 力作为一种治疗弥漫性毒性甲状腺肿的新型治疗手段，相关临床试验可以推动后 续该产品针对弥漫性毒性甲状腺肿人群的临床开发。 目前，GenSci098 注射液已于 2024 年 8 月同步在中国大陆及美国获批开展 用于甲状腺相关眼病（T ...

长春高新公告，公司近日获悉，控股子公司长春金赛药业有限责任公司下属全资子公司——上海赛增医 疗科技有限公司已根据其与Yarrow Bioscience,Inc.就GenSci098注射液项目订立的独家许可协议，收到 Yarrow一次性支付的7,000万美元首笔付款。目前，GenSci098注射液已于2024年8月同步在中国大陆及 美国获批开展用于甲状腺相关眼病（TED）的临床试验，并于2025年10月在中国大陆获批开展用于弥漫 性毒性甲状腺肿（GD）的临床试验。 ...

长春高新公告称，控股子公司金赛药业旗下赛增医疗与Yarrow就GenSci098注射液项目签独家许可协议 后，于2026年1月14日收到Yarrow一次性支付的7000万美元首笔付款，实际到账金额需扣除相关税金和 手续费。该协议2025年12月15日签订，赛增医疗将GenSci098注射液除大中华区外全球独家开发等权利 授权给Yarrow。GenSci098注射液为金赛药业自研，已在中美获批开展相关临床试验，此次付款将充实 公司现金储备，助力管线研发和国际化战略。 ...

来源：市场资讯 针对上述提问，长春高新回应称："您好，公司会结合市场需求、产品价格变化等情况，合理安排发货 等事宜，谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向长春高新提问："有机构称，公司长效生长激素进入医保后，各地都出现缺货， 请问实属吗？" ...

证券日报网讯1月14日，长春高新（000661）在互动平台回答投资者提问时表示，公司会结合市场需 求、产品价格变化等情况，合理安排发货等事宜。 ...

Core Viewpoint - Changchun High-tech's stock price has shown a significant increase this year, with a notable rise in recent trading days, despite a decline over the past two months [1][2]. Group 1: Stock Performance - As of January 13, Changchun High-tech's stock price increased by 2.01%, reaching 105.65 CNY per share, with a trading volume of 7.11 billion CNY and a turnover rate of 1.72% [1]. - Year-to-date, the stock price has risen by 14.15%, with a 10.12% increase over the last five trading days and a 12.81% increase over the last 20 days, while it has decreased by 12.88% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Changchun High-tech reported a revenue of 9.807 billion CNY, a year-on-year decrease of 5.60%, and a net profit attributable to shareholders of 1.165 billion CNY, down 58.23% year-on-year [2]. - The company has distributed a total of 4.791 billion CNY in dividends since its A-share listing, with 3.259 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Changchun High-tech was 104,100, a decrease of 4.63% from the previous period, with an average of 3,840 circulating shares per shareholder, an increase of 4.85% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 9.7451 million shares, an increase of 1.307 million shares from the previous period [3].

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.06% on January 12, with Sanofi leading the drop [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Dongbao Biological (300239) with a closing price of 6.60, up 10.92% and a trading volume of 575,100 shares, totaling 366 million yuan [1] - Changchun High-tech (000661) closed at 103.57, up 5.79%, with a trading volume of 169,400 shares, totaling 1.725 billion yuan [1] - ST Weiming (002581) closed at 7.83, up 4.96%, with a trading volume of 71,500 shares, totaling 54.3049 million yuan [1] - Conversely, significant decliners included: - Sanofi (688336) closed at 59.81, down 6.25%, with a trading volume of 93,200 shares, totaling 560 million yuan [2] - Teva Biopharma (688278) closed at 76.96, down 4.50%, with a trading volume of 41,600 shares, totaling 323 million yuan [2] - Aidi Pharmaceutical (688488) closed at 16.90, down 4.41%, with a trading volume of 98,600 shares, totaling 168 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 240 million yuan from institutional investors, while retail investors contributed a net inflow of 272 million yuan [2] - Key stocks with significant capital flow included: - Changchun High-tech (000661) had a net inflow of 122 million yuan from institutional investors, while retail investors saw a net outflow of 77.57 million yuan [3] - Dongbao Biological (300239) experienced a net inflow of 22.51 million yuan from institutional investors, with retail investors also seeing a net outflow of 10.81 million yuan [3] - Sanofi (688336) had a net inflow of 21.21 million yuan from institutional investors, while retail investors had a net inflow of 28.87 million yuan [3]

Group 1 - The core point of the news is that Changchun High-tech has seen a stock price increase of 5.09%, reaching 102.88 yuan per share, with a trading volume of 8.22 billion yuan and a market capitalization of 419.69 billion yuan as of January 12 [1] - Changchun High-tech is primarily engaged in the research, production, and sales of biopharmaceuticals and traditional Chinese medicine, with 92.83% of its revenue coming from the pharmaceutical sector, 6.81% from real estate, and 0.36% from services [1] - The company was established on June 10, 1993, and was listed on December 18, 1996, with its headquarters located in Changchun, Jilin Province [1] Group 2 - According to data from the top ten holdings of funds, Changchun High-tech is a significant holding in the Chuangjin Hexin Fund, specifically in the Chuangjin Hexin Xinxin Mixed A Fund (010605), which held 76,900 shares, accounting for 0.7% of the fund's net value [2] - The Chuangjin Hexin Xinxin Mixed A Fund has a total scale of 218 million yuan and has achieved a return of 0.88% this year, ranking 7492 out of 9012 in its category [2] - The fund manager, Liu Runzhe, has been in position for 3 years and 88 days, with the best fund return during his tenure being 20.1% and the worst being 1.92% [3]